Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Genotype guided therapy with MEK inhibition for patients with surgical arteriovenous malformations: a pilot phase I/IIa trial

EF 2022-23

Résumé
Arteriovenous malformations (AVMs) are a tangle of abnormal vessels that are prone to bleeding and can cause significant morbidity and mortality. Current treatment paradigms including surgery, radiation and embolization are often insufficient to treat this condition, leaving many patients with poor quality of life. In 2018, our lab showed that the overwhelming majority of AVMs are caused by a mutation that occurs after conception in the KRAS pathway, which is a well known pathway involved in cell proliferation, migration and vessel development. This pathway is also involved in other disease states including some types of cancers. Studies on mouse models and zebrafish showed that using an inhibitor of the KRAS pathway reverses the abnormal phenotype caused by this mutation. Trametinib is a commercial drug that targets a downstream effector of the KRAS pathway called MEK. It has been used in some of the cancers with KRAS mutations, such as metastatic melanoma. It has been approved for such diseases with not only good safety outcomes, but also reductions in tumour burden. Trametinib has recently been applied to some patients with palliative AVMs with no serious adverse events and reduction in the size and symptoms associated with the AVM. Our group has the largest experience to date with an ongoing observational study looking at the safety and efficacy of Trametinib for patients with palliative AVMs. Given the preliminary success with this drug, we now embark on an early pilot safety trial to formally assess (1) the safety of the drug in the surgical AVM population, as well as the impact of the drug on (2) patient symptoms and AVM characteristics on repeated scans, and (3) how Trametinib achieves these outcomes from a molecular point of view as determined by experiments on surgically resected AVM tissue after a couple months of treatment. This will be a groundbreaking study as it may open the door to oral drug therapies in this condition.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
474451
Name
Mansur Ann
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Genotype guided therapy with MEK inhibition for patients with surgical arteriovenous malformations: a pilot phase I/IIa trial
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Arteriovenous Malformations; Cerebrovascular Disease; Clinical Trial; Off-Label Drug Development; Stroke; Targeted Drug Therapy
Abstract
Arteriovenous malformations (AVMs) are a tangle of abnormal vessels that are prone to bleeding and can cause significant morbidity and mortality. Current treatment paradigms including surgery, radiation and embolization are often insufficient to treat this condition, leaving many patients with poor quality of life. In 2018, our lab showed that the overwhelming majority of AVMs are caused by a mutation that occurs after conception in the KRAS pathway, which is a well known pathway involved in cell proliferation, migration and vessel development. This pathway is also involved in other disease states including some types of cancers. Studies on mouse models and zebrafish showed that using an inhibitor of the KRAS pathway reverses the abnormal phenotype caused by this mutation. Trametinib is a commercial drug that targets a downstream effector of the KRAS pathway called MEK. It has been used in some of the cancers with KRAS mutations, such as metastatic melanoma. It has been approved for such diseases with not only good safety outcomes, but also reductions in tumour burden. Trametinib has recently been applied to some patients with palliative AVMs with no serious adverse events and reduction in the size and symptoms associated with the AVM. Our group has the largest experience to date with an ongoing observational study looking at the safety and efficacy of Trametinib for patients with palliative AVMs. Given the preliminary success with this drug, we now embark on an early pilot safety trial to formally assess (1) the safety of the drug in the surgical AVM population, as well as the impact of the drug on (2) patient symptoms and AVM characteristics on repeated scans, and (3) how Trametinib achieves these outcomes from a molecular point of view as determined by experiments on surgically resected AVM tissue after a couple months of treatment. This will be a groundbreaking study as it may open the door to oral drug therapies in this condition.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mansur, Ann
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~